康宁杰瑞制药-B(09966.HK) 公布,集团自主研发的用于治疗HER2表达晚期或转移性实体瘤的JSKN033的I/II期临床试验最新研究成果入选2024年SITC年会最新突破性摘要,且于年会期间以壁报形式首次公布。结论是JSKN033安全性良好,在多线治疗后疾病进展的实体瘤患者中初步显示出令人鼓舞的抗肿瘤活性。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-08 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.